Koninklijke DSM (OTCMKTS:RDSMY) was upgraded by equities research analysts at ING Group from a “sell” rating to a “buy” rating in a research note issued to investors on Wednesday, The Fly reports.
Several other equities analysts have also recently issued reports on RDSMY. JPMorgan Chase & Co. cut shares of Koninklijke DSM from an “overweight” rating to a “neutral” rating in a research report on Wednesday, September 1st. Morgan Stanley reaffirmed an “equal weight” rating on shares of Koninklijke DSM in a research note on Wednesday, August 4th. UBS Group reissued a “buy” rating on shares of Koninklijke DSM in a research note on Tuesday, August 24th. Societe Generale reaffirmed a “hold” rating on shares of Koninklijke DSM in a research note on Wednesday, August 4th. Finally, Barclays raised their price objective on shares of Koninklijke DSM from €168.00 ($197.65) to €189.00 ($222.35) and gave the stock an “overweight” rating in a report on Thursday, September 2nd. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $119.00.
RDSMY stock opened at $54.65 on Wednesday. The company has a 50 day simple moving average of $51.28 and a 200 day simple moving average of $47.19. The stock has a market cap of $39.66 billion, a price-to-earnings ratio of 66.65, a P/E/G ratio of 2.55 and a beta of 0.79. Koninklijke DSM has a 1 year low of $38.65 and a 1 year high of $54.93.
Koninklijke DSM NV engages in the manufacturing and sale of nutritional and pharmaceutical ingredients, and industrial chemicals. It operates through the following segments: Nutrition, Materials, and Innovation Center. The Nutrition segment comprises of the DSM Nutritional Products and DSM Food Specialties business groups.
Read More: Equity Income
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.